As if Biomarker Discovery Isn't Hard Enough: the Consequences of Poorly Characterized Reagents
Journal Article
·
· Clinical Chemistry, 60(1):290-291
The advent of high throughput omic technologies over the past two decades has driven a vast expansion in the search for clinical biomarkers, as manifested by the plethora of publications on biomarker discovery (over 8,600) listed on PubMed since 2000. Unfortunately, the same time period has seen a relative dearth of clinically validated biomarkers that have received FDA approval; only 10 new cancer biomarkers have been approved by the FDA in the same time period [1].
- Research Organization:
- Pacific Northwest National Lab. (PNNL), Richland, WA (United States)
- Sponsoring Organization:
- USDOE
- DOE Contract Number:
- AC05-76RL01830
- OSTI ID:
- 1130224
- Report Number(s):
- PNNL-SA-99249
- Journal Information:
- Clinical Chemistry, 60(1):290-291, Journal Name: Clinical Chemistry, 60(1):290-291
- Country of Publication:
- United States
- Language:
- English
Similar Records
Challenges in Biomarker Discovery: Combining Expert Insights with Statistical Analysis of Complex Omics Data
Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity
The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity
Journal Article
·
Tue Jan 01 00:00:00 EST 2013
· Expert Opinion on Medical Diagnostics, 7(1):37-51
·
OSTI ID:1130224
+4 more
Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity
Journal Article
·
Mon Mar 01 00:00:00 EST 2010
· Toxicology and Applied Pharmacology
·
OSTI ID:1130224
The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity
Journal Article
·
Sat May 15 00:00:00 EDT 2010
· Toxicology and Applied Pharmacology
·
OSTI ID:1130224